Feasibility Study of the DragonFire for Hypertrophic Obstructive Cardiomyopathy

Exclusion Criteria

• •1. Women who are pregnant, breastfeeding, or planning to become pregnant;
• •2. interventricular septum thickness ≥30mm;
• •3. non-hypertrophic obstructive cardiomyopathy;
• •4. Presence of cardiac neoplasms;
• •5. A history of interventricular septal resection or alcohol ablation, or Liwen surgery;
• •6. Combined with other heart diseases requiring surgical treatment;
• •7. Heart failure (after intensive anti-heart failure treatment, there are still symptoms of resting heart failure, such as left ventricular ejection fraction \< 50%, N-terminal -B type natriuretic peptide precursor, NT-pro BNP≥5000pg/ml, pulmonary edema, pleura or pericardial effusion, etc.);
• •8. Significant coronary lesions, or borderline lesions, requiring coronary revascularization due to mismatch between coronary perfusion and demand (QFR or FFR \< 0.8), or coronary ischemic events within 30 days;
• •9. Bleeding diseases or clotting disorders; Or there is a contraindication of antithrombotic drug therapy;
• •10. estimated Glomerular Filtration Rate (eGFR) \< 35ml/min;
• •11. Life expectancy was less than 12 months, and the investigator judged that the patient had poor compliance and could not complete the study as required; Or other circumstances in which the investigator considers the subject unsuitable for the study;
• •12. Subject is currently participating in an investigational drug or device study that has not completed its primary endpoint or that would clinically interfere with the endpoint of this study.